About US
Contact us
-
Merck cuts 148 jobs after giving up on ex-blockbuster hopeful ZontivityMerck & Co. ($MRK) has come to the end of the line with Zontivity, a clot-busting med once tagged with $5 billion sales estimates. The drugmaker won't promote the drug anymore in the U.S., and it2016/8/18
-
Vertex trial flop won't hurt chances for $485M revenue boost: AnalystsMonday, Vertex ($VRTX) announced plans to stop a cystic fibrosis trial that was coming up empty. But it wasn’t all bad news for the drugmaker--and analysts even managed to pull out some positives. Ca2016/8/17
-
Orphan drugs used in wider settings come with sizable price hikes, report findsPassed in 1983, the Orphan Drug Act (ODA) has spurred development of hundreds of rare disease drugs that may have not otherwise seen the light of day. But many drugs under the “orphan” umbrella are us2016/8/17
-
On day one of cancer fund overhaul, NICE faces new calls for reformToday is the first day forEngland’s drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICEfaced criticism froma top drugmaker over how it intends t2016/8/16
-
England's NHS waged a tense behind-the-scenes fight against pricey hep C drugsWhen England’s cost-effectiveness gatekeepers gave their blessing to Gilead Sciences’ pricey hepatitis C drugs last year, some of the country’s sickest patients were already being treated under a spec2016/8/16
-
FDA amps up black-box warnings on antibiotic class that includes J&J's Levaquin, Bayer's CiproThe FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black-box warning. The agency also advised using the drugs only for serio2016/8/15
-
BMS' Opdivo, Amgen's Repatha first on Japan's list for new price restrictionsPharma, already smarting in Japan from new price controls imposed by the government, may now face additional limits on new breakthrough drugs. Up first for challenge are Bristol-Myers Squibb’s hot-sel2016/8/15
-
M&As this week: Arterium Corporation, Guanhao BiotechOriginal and generic pharmaceutical product providerArterium Corporationhas acquired pharmaceutical company Marifarm from Novo KBM d,d. to strengthen its research and development (R&D) and product2016/8/12
-
Janssen’s Imbruvica receives SMC recommendation for blood cancer treatmentThe Scottish Medicines Consortium (SMC) has recommended pharmaceutical company Janssen’s Imbruvica (ibrutinib) treatment for use in Scottish patients with specific types of rare and aggressive blood c2016/8/12
-
New study reveals warfarin may be ineffective for atrial fibrillation over long-termA study conducted by US-based Duke Clinical Research Institute researchers has revealed that warfarin, a drug prescribed to prevent strokes in patients with atrial fibrillation, may not be able to ade2016/8/11